Breaking News, Collaborations & Alliances

Repligen Earns Pfizer Milestone

Receives $1 million under SMA development pact

Repligen Corp. has received a $1 million milestone payment from Pfizer under an exclusive worldwide licensing agreement for the development of compounds to treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two.
 
The companies signed the agreement in January 2013, and since then, Repligen has received $7 million in upfront and milestone payments. Repligen is eligible to receive as much as $63 million in additional milestones, as well as royalties on any future sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters